Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings

Here's Why You Should Offload Dana Stock From Your Portfolio

Dana Incorporated (DAN), an automotive supplier, has lowered its 2026 adjusted EPS guidance to $1.75-$2.25 from $2-$3 due to weak EV orders, lower China joint venture earnings, and higher capital spending. The company faces $59 million in EV program termination charges through H1 2026 and execution risks from the Eaton Mobility integration. Despite improving EBITDA, free cash flow growth remains limited by elevated capital expenditures.

Shares of automakers, recreational vehicle makers and auto-parts companies are trading lower after President Trump said in a social media post that tariffs on cars and trucks and automotive parts from Canada will be increased to 50% from January 1, 2027.

Barclays Maintains Equal-Weight on Dana, Raises Price Target to $35

Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.

William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.